Pancreatic ductal adenocarcinoma (PDAC) being characterized by a pronounced stromal compartment is commonly diagnosed at an advanced stage limiting curative treatment options. Although therapeutical targeting of immune checkpoint regulators like programmed death 1 ligand 1 (PD-L1) represent a promising approach that substantially improved survival of several highly aggressive malignancies, convincing indicators for response prediction are still lacking for PDAC which might be attributed to the insufficient characterization of PD-L1 status. Therefore, we investigated PD-L1 expression by immunohistochemistry in a well characterized cohort of 59 PDAC and 18 peritumoral tissues. Despite the histopathological homogeneity within our cohort, tumor tissues exhibited a great heterogeneity regarding PD-L1 expression.
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer related deaths in Western countries [1] . The dismal 5-year survival rate of < 8% is mainly attributed to the lack of reliable biomarkers and screening methods for early detection of the tumor. Therefore, more than 80% of PDAC patients are diagnosed Research Paper www.oncotarget.com at locally advanced or metastatic stages [2] . However, despite the advances in research on PDAC development and progression, palliative chemotherapy represents the only treatment option for patients with unresectable tumors [3] .
The extensive desmoplastic stroma, which constitutes almost 80% of the tumor mass, has been shown to promote aggressiveness and treatment resistance of PDAC [4] . Highlighting the role of the cellular stromal compartment, the increased presence of immunosuppressive cell populations, e.g. tumor-associated macrophages (TAMs) and regulatory T cells (T regs ), is related to a poor prognosis [5, 6] . Hence, immunotherapeutical approaches are promising novel strategies to reactivate tumor directed immune responses. Based on the impressive response rates in several other malignancies, e.g. non-small cell lung carcinoma and melanoma, blocking of the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) signaling pathway currently represents one the most intensively investigated immune therapies for the treatment of PDAC [7] .
PD-1 is a type I transmembrane protein that belongs to the immunglobulin B7 superfamily receptors. PD-1 is mainly expressed by T lymphocytes and downstream signaling due to activation by PD-L1 or PD-L2 participates in the coinhibitory regulation of T cell proliferation, activation and proinflammatory cytokine expression [8] . PD-L1, also known as B7-H1 or CD274, is expressed by different immune cell populations including dendritic cells (DC), macrophages as well as T and B cells. However, abberant PD-L1 expression by malignant cells has been identified in several solid tumors and, therefore, constitutes one important immune escape mechanism [9] .
The identification of PDAC patient subgroups that benefit from the application of PD-1 or PD-L1 blocking antibodies is not only the key to an effective therapy concept, but also essential for the understanding of tumor biology and treatment adaption in the course of tumor progression. PD-L1 expression status in the tumor might serve as an indicator for therapy response and stratification of patients. However, PD-L1 status is actually a controversially discussed topic since detection and classification of PD-L1 status is not standardized and based on different diagnostic antibodies and threshold definitions [10] . Moreover, it is questionable if the common classification system that only rates PD-L1 expression in tumor but not stromal cells is sufficient for precise prediction and/or prognostic purposes in PDAC therapy. Thus, the aim of this study was to comprehensively characterize PD-L1 expression in stromal and tumoral compartment via IHC in a well characterized collective of 59 PDAC tissues and 18 peritumoral pancreatic tissues. For this purpose, we developed a scoring system (POLE Score) that considers PD-L1 expression, in both tumor and stromal cells, in terms of (i) overall PD-L1 expression (P) (ii) cellular origin of PD-L1 (O) (iii) PD-L1 expression in tumorassociated lymph follicles (L) and (iv) enumerated local PD-L1 distribution (E). Finally, we applied this system to the tissue sections and correlated the results with clinicpathological data as well as findings from IHC studies on markers for proliferation, lymphocyte infiltration and epithelial to mesenchymal transition (EMT) status.
RESULTS

Heterogenous PD-L1 expression in tumor tissue from PDAC patients
Immunostaining on PD-L1 was performed on whole tumor sections of 59 PDAC patients focusing on PD-L1 expression in neoplastic cells, stromal cells within the desmoplastic reaction as well as tumor-associated lymph follicles (Supplementary Table 1 ). We identified prominent intra-and intertumoral differences in PD-L1 expression with regard to staining intensity and proportion of PD-L1 + cells. Therefore, staining intensities were scored from 1 to 3 (weak, moderate and strong) ( Figure 1A-1C) and proportion of PD-L1 + cells was rated from 0 to 2 (0%, ≤ 1% and > 1% PD-L1 + cells) ( Figure 1D -1F) in each microscopic field of view (FoV). Moreover, comparison of PD-L1 expression within tumor-associated lymph follicles with remaining tumor tissue exhibited frequently marked differences. Hence, PD-L1 expression of each tumorassociated lymph follicle was scored separately according to its respective intensity from 0 to 2 (negative, weak, strong) ( Figure 1G-1I ). Lymph Score was calculated based on the median value of all lymph follicles within the tissue section. Excluding tumor-associated lymph follicles, we observed areas in the tumoral and stromal compartment of PDAC tissues that showed scattered distribution of PD-L1 + cells as well as those that exhibited dense clusters of PD-L1 + neoplastic and/or stromal cells ( Figure 1J, 1K) . Thus, the respective pattern within each PD-L1 + FoV was rated as 0 (scattered) or 1 (clustered) and Cluster Scores were calculated by mean values of rated FoV within the respective tissue section. Lymph and Cluster scores of PDAC tissue sections ranged from 0 to 2 with a median of 1 (Lymph Score) and from 0 to 0.52 with a median of 0.14 (Cluster Score), respectively.
Although some of the tissues exhibited areas with pronounced PD-L1 expression, the low overall presence of PD-L1 + cells in 44 of 56 cases (78.6%) led to Quantity and Intensity Scores of 0. In order to better discriminate between sections with small PD-L1 + areas and particularly high PD-L1 expression, an immunreactivity scoring (IRS) system was applied. Therefore, Quantity and Intensity Scores were sumed up for each rated FoV and mean values were calculated for the whole tissue section (Tissue Score). Tissue Scores revealed values in the range from 0 to 2.65 with a mean score of 0.55.
As an additional indicator for overall distribution of PD-L1 + cells within the tumor, proportion of FoV graded www.oncotarget.com with an IRS > 0 (%FoV + ) has been documentated for each tissue section. Proportion of PD-L1 + FoV within PDAC tissue sections ranged from 0 to 92.4% with a median proportion of 22.9%. Results from IHC staining evaluation are summarized in Table 1 .
PD-L1 expression is higher in tumor tissue of PDAC patients compared to peritumoral pancreatic tissue
In order to examine whether PD-L1 is higher or even exclusively expressed in PDAC tumor tissue compared to peritumoral pancreatic tissue, we analyzed PD-L1 expression within 18 peritumoral tissue sections from PDAC patients. Application of the established scoring system (Table 1 ) revealed a significantly lower proportion of PD-L1 + FoV in peritumoral pancreatic tissue sections compared to tumor tissue sections (12.2% vs. 22.9%) (Figure 2A ). Accordingly, correlation of PD-L1 expression in the 13 peritumoral tissue sections and their corresponding tumor sections revealed significantly higher Tissue Scores in tumor tissues compared to peritumoral tissues (Tissue Score ratio: 0.144) ( Figure 2B, 2C) . Notably, 4 of 18 peritumoral tissue sections exhibited comparatively high Tissue Scores (≥ 0.8) and high proportions of PD-L1 + FoV (> 30%) ( Figure 2D ). In comparison to the other peritumoral tissues, these tissue sections exhibited a higher proportion of malignant cells within the tumor margin, indicating that enhanced intratumoral PD-L1 expression in PDAC might be related to the local proximity and proportion of neoplastic cells. Interestingly, in contrast to tumor tissue sections, peritumoral tissues revealed no PD-L1 negative lymph follicles. Furthermore, Cluster Scores > 0.4 were exlusively found in neoplastic pancreatic tissues (Table 1) .
PD-L1 Tissue Score correlates with survival and tumor grade in PDAC
Despite the pathological homogeneity within our cohort (98% T3 and 87% T3N1M0), survival markedly differed between patients (0-108 months). Therefore, we examined whether PD-L1 Tissue Score correlates with patient survival. Indeed, we found a significant correlation between a Tissue Score > 0. 8 
PD-L1 is predominantly expressed by stromal cells in PDAC
In the concept of PD-1/PD-L1 targeting therapy, aberrant PD-L1 expression by malignant cells is regarded as a crucial immune escape mechanism [11] . However, also stromal PD-L1 expression might contribute to the immunosuppressive microenvironment in PDAC. In order to discriminate tumoral-and stromal-associated PD-L1 expression, we performed PD-L1/PanCK IHC staining of PD-L1 high classified PDAC tissue sections. Cell Scores resulting from this analysis indicate whether PD-L1 is primarily expressed by epithelial/ cancer cells (Cell Score 1; Figure 3A -3C), stromal cells (Cell Score 2; Figure 3D -3F) or whether PD-L1 is expressed by both populations to a similar extent (Cell Score 3; Figure 3G- Figure 3J ). 
Improved characterization of PD-L1 expression status in PDAC by POLE Score
In order to consider all information obtained from PD-L1 expression analyses, we developed a comprehensive characterization score that resembles the TNM staging system. For this purpose, compiled Tissue, Cell, Lymph and Cluster Scores were converted into a four-letter code (POLE Score) that characterizes intratumoral overall PD-L1 expression (P), cellular Origin of expressed PD-L1 (O), PD-L1 expression status in tumor-associated Lymph follicles (L) and the Enumerated local distribution of PD-L1 + cells (E) by single digits. Characterization criteria of each POLE Score parameter are summarized in Table 2 .
According to these criteria, collected data on PD-L1 expression within our cohort of PDAC tissues were converted into respective POLE Scores ( Figure 4A ). P-Score proportion indicated that PD-L1 is markedly expressed in 30.4% (P2) of PDAC tissues, while it is low expressed in 25.0% (P1) and absent or almost absent in 44.6% (P0) of the specimens ( Figure 4B ). Notably, 76.5% of P2 rated tissues showed either almost exclusive (O2, 53.0%) or prominent (O3, 23.5%) PD-L1 expression within the stroma ( Figure 4B ). In comparison to the entire cohort, P2 graded tissues revealed no PD-L1 -lymph follicles ( Figure 4B ). Moreover, only P0 scored tissues comprised sections rated L0 ( Figure 4A ). Finally, all PDAC tissues markedly enriched for PD-L1 + cell clusters (E1) belonged to the P2 classified subgroup ( Figure 4B ).
Correlation of PD-L1 expression and tumor stromal composition
Since the present cohort of PDAC tissues has been already extensively characterized regarding tumor stromal composition, proliferation and EMT status, we correlated available data from previous immunohistochemical studies [12] with POLE Scores (Supplementary Table 2 ). For this purpose, POLE Scores (except for E-Score) were dichotomized prior to statistical analyses into: Figure 1) . Finally, PDAC tissue sections exhibiting prominent formation of PD-L1 + cell clusters (E1) were only found within the +P2 subgroup. Accordingly, 30 of 36 E0 rated specimens showed low overall PD-L1 expression ( Figure 5H ).
Taken together, our data indicate that PD-L1 expression in PDAC markedly varies in terms of different tumor compartments (neoplastic vs. stromal cells vs. tumor-associated lymph follicles) and correlates with distinct patterns of tumor/stromal composition. 7J, 7N, 7K, 7O) . Interestingly, α-SMA expression within these areas was low in comparison to overall intratumoral α-SMA expression (Figure 7L, 7P Figure 8A ). Flow cytometric analyses of tumor specimens from three PDAC patients well reflected the described tumor heterogeneity of PD-L1 expression in PDAC. TAMs could be detected in two specimens: one of these specimens exhibited a TAM population mainly composed of PD-L1 + cells (87.9 %) ( Figure 8B ) with a median fluorescence intensity ratio of 2.53 ( Figure 8C ) indicating high cell surface expression levels. In contrast, the other specimen revealed a minor population of PD-L1 + TAMs (7.2 %) ( Figure 8B ) and lower median fluorescence intensity ratio (1.55) ( Figure 8C ). Furthermore, PD-L1 expression by CD68 + TAMs was validated by double immunofluorescence stainings of PDAC tissue sections clearly showing that CD68+ cells express PD-L1 ( Figure  8D ). However, similar to the flow cytometric analysis immunofluorescence stainings also revealed that not all TAMs express PD-L1 indicating that other stromal cells also account for PD-L1 expression in PDAC.
In line with our previous results, these findings also demonstrate that only a small proportion of panCK Further supporting these data, western blot analyses showed that PD-L1 expression is nearly absent in PDAC cells but pronounced in in vitro differentiated macrophages ( Figure 8E ). These findings also revealed that both GM-CSF and M-CSF are potent inducers of PD-L1 expression in monocytes and macrophages ( Figure  8E ). Notably, GM-CSF differentiated macrophages being characterized by a rather pro-inflammatory phenotype (M1 Mφ) exhibited considerably higher PD-L1 expression levels than M-CSF differentiated antiinflammatory macrophages (M2 Mφ).
Altogether, these findings support the view that PDAC cells rarely express high PD-L1 levels at the cell surface while TAMs represent one stroma cell population acccounting for high PD-L1 expression in PDAC. 
DISCUSSION
Restoring anti-tumoral immune response by interference with coinhibitory PD-1/PD-L1 signaling currently represents one of the most promising and most intensively investigated strategies in cancer therapy [13] [14] [15] . However, although the theory behind its mode of action seems to be simple, the tumor-specific characteristics that either favor or impede effective PD-1/PD-L1 targeting are insufficiently understood. In this context, a major challenge is to reliably identify patients that benefit from PD-1/PD-L1 blockade. While several preclinical studies proposed PD-L1 expression as a predicative marker, correlations between treatment responses and respective tissue based PD-L1 status in clinical trials are still poor, absent or contrary [16] [17] [18] [19] . Moreover, assessment of PD-L1 status itself is controversially discussed, since neither detection systems nor classification criteria are standardized [10] . Underlining the questionable significance of current methods for PD-L1 status assessment, results from phase I of the ongoing Blueprint study indicate that available assays that only rate PD-L1 expression by neoplastic cells lead to contrary classifications of PD-L1 status in 37% of the cases [20] . As a result, current indications for application of PD-1/PD-L1 blocking antibodies are either non-existent or failure of standard oncological treatment regimens in most cases. To our knowledge, there are at least nine others studies that reported PD-L1 expression in PDAC [21] [22] [23] [24] [25] [26] [27] [28] [29] . However, this study is the first which provides a comprehensive charaterization (POLE Score) that considers PD-L1 expression by tumor and stromal cells in PDAC. We identified three subgroups within our cohort that were categorized into absent (P0), low (P1) and high (P2) PD-L1 expression. Supporting this finding, Birnbaum et al. identified a similar proportion of cases exhibiting high PD-L1 expression on mRNA level within a cohort of 453 pancreatic cancer tissues [26] . In general, recent data suggest that prominent PD-L1 expression in PDAC is restricted to a minor subgroup of tumors. Notably, PD-L1 expression seems not to correlate with pathological staging, since we detected marked differences within our homogenous cohort (87% T3N1M0). However, in line with the results by Wang et al. and Geng et al., we showed that PD-L1 expression rather correlates with tumor grade, indicating a link between loss of tumor differentiation and immune regulation [22, 25] . With regard to the prognostic ) and in vitro differentiated human macrophages. Macrophages were generated by stimulation of isolated monocytes from healthy donors with either 50 ng/mL GM-CSF (M1 Mφ) or M-CSF (M2 Mφ) for 7 days. Hsp90 was detected as loading control. Upper box shows PD-L1 signal from PDAC cell line lysates after increased light exposure. www.oncotarget.com significance of our POLE Score, we and others found a reduced overall survival in the subgroup of patients with PD-L1 high classified tumors compared to those with PD-L1 low tumors [21, 26] . In contrast, other studies reported a better prognosis in terms of overall or progressionfree survival associated with high PD-L1 expression in PDAC and other malignancies [27, 28, 30] . Still, survival correlations in PDAC need to be examined critically, since recovery from surgery and the presence of clinically nondetectable micrometastases in tumors classified as M0 or resected as R0 represent unknown variables that massively affect clinical outcome [31] [32] [33] .
One of the key innovations of our study is the discrimination between PD-L1 + neoplastic and stromal cells. Demonstrating that PD-L1 is predominantly expressed by stromal cells, we underline that common classifications considering only PD-L1 + tumor cells exclude a major population of PD-L1 + cells in PDAC that might have tumor biological and therapeutical significance. In line with these observations and supporting the clinical importance of stromal PD-L1 expression, several pre-clinical studies highlighted the presence and prognostic relevance of PD-L1 expressing immune cell populations [34] [35] [36] [37] [38] [39] [40] . Here, we show that accumulation of PD-L1 + tumor and stromal cells is associated with local high infiltration of CD8 + T cells and CD68 + T cells in human gastric adenocarcinoma and PDAC, respectively [35, 36] . Local PD-L1 expression might be induced by CD8 + T cell secreted IFN-γ being one of the most potent inducers of PD-L1 [36, 41] . Moreover, our in vitro studies showed that GM-CSF and M-CSF differentiated M1-and M2-like polarized macrophages exhibit considerable PD-L1 expression and that GM-CSF secreted by T cells and fibroblasts but also cancer cells enhance PD-L1 expression in monocytes (unpublished data). This might also explain the fact that our data suggest the local proximity of malignant cells within the desmoplastic tumor margin as a requisite for accumulation of PD-L1 + stromal cells. Furthermore, since CD163 is a prominent marker of anti-inflammatory or M2-like polarized TAMs, recruited M2-like polarized TAMs might impede potent effector T cell responses. In this context, we and others previously reported on the role of M2-polarized TAMs in tumor progression of PDAC [42] [43] [44] . Supporting our hypothesis of local CD8 + T cell response suppression by TAM-associated PD-L1 expression, both Zhang et al. and Kleinovink et al. showed in murine models of PDAC and colon carcionoma that myoleid cells substantially contribute to tumor initiation, growth of established tumors and suppression of CD8 + T cell response via self and induction of tumor cell-associated PD-L1 expression [45, 46] . Nevertheless, we also identified cases in which PD-L1 expression was exclusively restricted to tumor cells. Supporting the assumption that genomic alterations acquired during malignant transformation might cause the ability for aberrant PD-L1 expression in pancreatic ductal epithelial cells, we showed that ducts in peritumoral tissues lack PD-L1 expression and that most PDAC cell lines were characterized by low PD-L1 expression. However, not all PDAC cell lines responded towards IFN-γ stimulation with enhanced PD-L1 expression (unpublished data). Therefore, results from other studies suggest that malignant cells expressing PD-L1 might play a central role in distinct processes of tumor progression, e.g. dissemination of circulating tumor cells and metastasis [47] .
Finally, our findings also suggest that PD-1/ PD-L1-mediated signaling in PDAC constitutes an immunosuppressive mechanism that is predominantly restricted to the tumor margin and tumor-lymph follicle interface but not the whole tumor. In line with preliminary results from an ongoing phase 2 clinical trial using PD-L1 antagonist Durvalumab in monotherapy for the treatment of metastatic PDAC (NCT02558894), our results implicate that the clinical benefit of therapeutically targeting PD-1 or PD-L1 in monotherapy might be limited. Therefore, it has to be considered that PD-L1 represents just one of several immunoregulatory molecules within the immunosuppressive stroma of PDAC and further studies are needed to unravel the clinical relevance of tumor-and stromal-associated PD-L1 expression within this complex network.
CONCLUSIONS
This study provides a detailed characterization of PD-L1 expression in PDAC and indicates that PD-L1 expression and its tumor biological relevance have to be rated context dependent, but individual consideration of PD-L1 status might not be applicable for stratification of PDAC patients. Applying the POLE Score, we identified strong correlations between specifically locally restricted PD-L1 expression and stromal composition. Notably, we showed that PD-L1 is predominantly expressed by stromal cells in PDAC, a factor whose role in both tumor biology and immunotherapy is poorly understood, yet. However, validation of our POLE scoring system in an independent PDAC cohort and future clinical trials have to evaluate whether POLE Score might serve as a predictive marker for efficient immunotherapy in PDAC.
MATERIALS AND METHODS
Ethics statement
The research was approved by the ethics committee of the University Hospital Schleswig-Holstein (reference number: D430/09). Written informed consent was obtained from all patients. www.oncotarget.com 
Tissues & study population
Histology
Tissue specimens were fixed in formalin and embedded in paraffin (FFPE). Deparaffinized sections were stained with hematoxilyn and eosin. Tumor grade and stage were classified according to the 7th edition of the UICC guidelines.
Immunohistochemistry
Immunohistochemical PD-L1 stainings of pancreatic FFPE tissue sections were carried out with a Bondmax automated slide staining system, using the Polymer Refine Detection Kit (both Leica Biosystems, Wetzlar, Germany) and a rabbit monoclonal anti-PD-L1 antibody (8.76 µg/ml, clone #E1L3N, Cell Signaling, Frankfurt a.M., Germany). Specificity of the staining was ensured by application of a respective rabbit IgG isotype control revealing no staining. All other stainings were performed and are described in a former study [12] .
Evaluation of PD-L1 staining
Pancreatic tissue sections of PDAC patients were immunohistochemically stained with a monoclonal antibody against PD-L1 and screened at 200-fold magnification using an Axioplan 2.0 microscope (Zeiss, Jena, Germany). Since whole tissue sections (~ 1-6 cm 2 area) were analyzed, evaluation of each tumor comprised up to 800 microscopic fields to properly consider tumor heterogeneity. Each field of view (FoV) (Diameter = 0.87 mm at 200-fold magnification) was rated regarding the percentage of PD-L1 positive cells and the mean staining intensity of stained cells. While for PD-L1 expression in tumor cells only the membranous staining was evaluated, stromal cells were rated positive when stained regardless of the cellular PD-L1 localisation. Furthermore, only ductal epithelial, tumor and stromal cells were included in the rating, while fat tissue, neural and acinus cells were excluded. Lymph follicles were rated seperately. The following immunoreactivity scoring system (IRS) was applied for each FoV: (I) the presence and percentage of PD-L1 + cells were graded as 0 (negative), 1 (≤ 1% positive) or 2 (> 1% positive), (II) the mean staining intensity of FoV comprising PD-L1 + cells were graded as 1 (weak), 2 (moderate) or 3 (strong). Total number of graded FoV depended on the size of the tumor tissue section (30-600). Hereafter, the IRS for each FoV was calculated by summation of both scores resulting in values ranging from 0 to 5. Finally, the "Tissue Score" for each specimen was determined by calculating the mean value of its total IRS scores. In order to characterize the scattering of PD-L1 positive cells within each tissue section, the proximity of PD-L1 expressing cells towards each other within FoV with an IRS >0 was graded as 0 (PD-L1 positive cells are widely distributed) or 1 (formation of PD-L1 + cell cluster). The resulting "Cluster Score" for each specimen represents the mean value of all rated FoV resulting in values between 0 and 1. In order to score PD-L1 expression in tumor-associated lymph follicles, staining intensity within each follicle was graded as 0 (negative), 1 (weak) or 2 (strong). The resulting "Lymph Score" for each specimen represents the median value of all rated lymph follicles. 
PD-L1
+ cells were rated as 2. Cell Scores 1 (≥ 90% FoV rated as 1), 2 (≥ 90% FoV rated as 2) and 3 (∑FoV=1 ≈ ∑FoV=2) are based on the overall proportion of FoV graded as 1 or 2 within the tissue section. All evaluations were performed twice in a blinded manner. In case of discrepant results, sections were additionally evaluated by a second investigator.
Isolation of cells from fresh PDAC tissues and flow cytometric analysis
Fresh tumor tissues were obtained from PDAC patients during surgery at the Community Hospital in Kiel. Histopathological diagnosis was performed by board certified surgical pathologists at the Institute of Pathology of the Community Hospital in Kiel. Isolation of vital tumor and stromal cells from PDAC tissues was performed with the Tumor Dissociation Kit (human) (Miltenyi Biotec, Bergisch-Gladbach, Germany). Briefly, tumor tissue was cut with a scalpel into pieces of approximately 0.5 mm 3 in size and incubated in 10 ml RPMI 1640 supplemented with an enzyme mix provided by the kit for 1 h at 37° C www.oncotarget.com on a roller mixer. Afterwards, remaining undissociated tissue pieces were filtered out with cell strainers (mesh sizes: 100 µm and 30 µm) and the filters were washed with 20 ml RPMI 1640. After centrifugation at 300 × g for 10 min at 4° C, cells were washed in cold MACS buffer (PBS supplemented with 2% FCS and 1 mM EDTA) and counted. Before staining for flow cytrometric analysis, Fc receptor blocking was performed with FcR Blocking Reagent (human) (Miltenyi Biotec) according to the manufacturer's instructions. For extracellular staining of cell surface proteins, 1-5 × 10 5 cells were incubated for 30 min at 4° C with following fluorochrome-conjugated antibodies: anti-human CD45-BV510 (clone #HI30, 4 µg/ml) (Biolegend, Fell, Germany) and anti-human PD-L1-PE-Cy7 (clone #MIH1, 20 µg/ml) (BD Bioscience, Heidelberg, Germany). Afterwards, cells were washed twice and subjected to permeabilization with Intracellular Fixation and Permeabilization Buffer Set (Thermo Scientific, Schwerte, Germany) for intracellular staining according to the manufacturer's instructions. For intracellular staining, cells were cells were incubated for 20 min at 4° C with following fluorochrome-conjugated antibodies: anti-human cytokeratin-FITC (clone #CK3-6H5, 0.4 µg/ml) (Miltenyi Biotec) and anti-human CD68-APC (clone #Y1/82A, 0.5 µg/ml) (Biolegend). Finally, cells were washed twice and stored in MACS buffer supplemented with 1% PFA until analysis with an LSRFortessa flow cytometer (BD Bioscience). Staining specificities were verified by stainings with respective isotype controls and compensation was adjusted with single stainings. Evaluation was performed with FlowJo v10 (FlowJo LCC, Oregon, US).
Immunofluorescence staining
Serial FFPE tissue sections from PDAC patients that exhibited high PD-L1 expression in previous IHC stainings were subjected to immunofluorescence co-staining for CD68 and PD-L1. Briefly, FFPE tissue sections were deparaffinized with Xylene and rehydrated with a descending alcohol series. Afterwards, tissue sections were washed in PBS before antigen-retrieval was performed by incubation in a steamer for 20 min in pre-warmed citrate buffer pH 6.0. For all following incubation steps, tissues were placed in a humified chamber. After cooldown to room temperature (RT), endogenous peroxidases were blocked by incubation in stabilized 3% (v/v) H 2 O 2 solution (Thermo Scientific) for 1 h at RT. Then, quenching of tissue autofluorescence was performed via incubation in 70% (v/v) ethanol in ddH 2 O supplemented with 0.1% (w/v) Sudan Black B (Sigma-Aldrich, Munich, Germany) for 20 min at RT. After washing thrice in PBS, serum block was performed by application of 10% goat serum (Thermo Scientific) on tissue section for 1 h at RT. Hereafter, tissues were incubated over night at 4° C with following primary antibodies: anti-human PD-L1 (clone #E1L3N, 8.76 µg/ml) (Cell Signaling) and anti-human CD68 (clone #514H12, 0.37 µg/ml) (Leica Biosystems, Wetzlar, Germany). Following secondary antibodies were applied for 1 h at RT: goat-anti mouse IgG (H+L)-Alexa Fluor 546 (2 µg/ml) (Thermo Scientific) and goat anti-rabbit IgG-Poly-HRP (provided by the Alexa Fluor 488 Tyramide SuperBoost Kit purchased from Thermo Scientific). Detection of PD-L1 via HRP-antibody complex was achieved by incubation of tissue sections for 10 min in supplied Reaction Cocktail before adding Reaction Stop Solution (both provided by Tyramide SuperBoost Kit, Thermo Scientific). Finally, Hoechst (2 µg/ml) was used for nuclei staining, tissue sections were mounted in FluorSave reagent (Merck Millipore, Darmstadt, Germany) and sealed with clear nail polish by a coverslip. Staining evaluation and image acquisition was performed with a Lionheart FX Automated Microscope (BioTek Instruments, Bad Friedrichshall, Germany).
Cell lines and cell culture
PDAC cell lines Panc-1, PancTu-I, Panc-89, COLO357, BxPC-3 and were cultured in RPMI 1640 supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine and 1% sodium pyruvate (all Biochrom, Berlin, Germany). MIAPaCa-2 cells were cultured in DMEM high glucose, 10% FCS, 2.5% horse serum (Thermo Fisher Scientific, Schwerte, Germany) and 1% L-glutamine. Isolation of primary human monocytes from healthy donors and in vitro differentiation of macrophages was described previously [42] . Informed consent was obtained from all donors. Authentification of cell lines was performed by STR analysis.
Western blotting
Preparation of whole-cell lysates, electrophoresis and Western blotting were described previously [48, 49] . The following antibodies were used according to the manufacturer's instructions: rabbit anti-Hsp90α/β (clone H-114, Santa Cruz Biotechnology, Heidelberg, Germany) and rabbit anti-PD-L1 (clone E1L3N).
Statistical analysis
Statistical analysis was performed using SigmaPlot 12.5 (Systat Software Inc., Chicago, United States of America). All results were examined as raw scores, catagorized by dichotomization and resulting values were compared between groups by Chi-square or Fisher Exact test. Groups of datasets were tested for normal distribution and equal variance by Shapiro-Wilk and Equal Variance test, respectively. Two groups of datasets which failed normality or equal variance test were analyzed by Mann-Whitney Rank Sum test. Non-parametric datasets comprising more than two groups were analyzed by Kruskal-Wallis One-Way Analysis of Variance (ANOVA) on Ranks test. Survival curves were estimated according to Kaplan-Meier method and potential influence factors
